Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia

Summary

This is a phase II, prospective, multicenter, open-label study to evaluate the efficacy and safety of Alemtuzumab in patients with relapse and refractory B-cell chronic lymphocytic leukemia.

Timeline

Start

2011-07

Primary completion

2021-02

Completion

2022-06

Outcome

Outcome not reported

Stopped (Enrollment): “recruiting difficulties”

Drugs

Indications